Important Additional Information about the Tender Offer Information regarding these and other risks related to King's business, investors should consult King's most recent Annual Report on Form 10-K for the yearĮnded Decemand King's quarterly reports on Form 10-Q and other documents filed by King with the U.S. Forward-looking statements involve risks and uncertainties. Temporary nature of the unrealized losses recorded in connection with these securities. The expected timing of the initial marketing of certain products products developed, acquired or in-licensed that may be commercialized King's intent, beliefs orĬurrent expectations, primarily with respect to future operating performance expectations regarding sales growth, gross margins, manufacturing productivity,Ĭapital expenditures and effective tax rates expectations regarding the outcome of various pending legal proceedings expectations regarding King's financialĬondition and liquidity as well as future cash flows and earnings expectations regarding the ability to liquidate King's holdings of auction rate securities and the
Outcomes and timing of research, clinical trials and other development activities involving pharmaceutical products the development of product line extensions Strategic shift anticipated developments and expansions of King's business plans for the manufacture of some of King's products the potential costs, ("Alpharma") and King and any necessary actions to obtain required regulatoryĪpprovals the potential of King's branded pharmaceutical products expectations regarding the enforceability and effectiveness of product-related patents Įxpected trends and projections with respect to particular products, reportable segment and income and expense line items the adequacy of King's liquidityĪnd capital resources anticipated capital expenditures the acceptance, priority review or approval of certain New Drug Applications the development,Īpproval and successful commercialization of certain products the successful execution of growth and restructuring strategies, including King's accelerated Such statements are based on management's current expectations, but actual results may differ materially due to various factors such as King'sĪbility to complete the tender offer as expected King's ability to achieve the synergies and value creation contemplated by the proposed transaction King'sĪbility to promptly and effectively integrate the businesses of Alpharma Inc.
All statements contained in this document that are not clearly historical in nature or that necessarily depend on future eventsĪre forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking
#Neutra text tf sc update
("King") disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking This document contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). No materials contained in this presentation shall be reproduced or redistributed in any form.Ĭreates a Leading Specialty Pharma Company
0 kommentar(er)
